Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122896 · ClinicalTrials.gov registry record · Early Phase 1
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
A Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 5,000
- Enrollment target
- 2
- Study locations
NCT06122896: Recruiting Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Dana-Farber Cancer Institute.
NCT06122896 is a Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 5,000 participants, above the 375-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (1233% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06122896, a Early Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 5,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
Primary Outcome
Subjects will be counted in this metric if they have pathological tissue confirmation of a pancreatic cancer or high-grade dysplasia during each observation period.
Conditions Studied
Interventions
- OTHER Screening Blood Tests
- DIAGNOSTIC_TEST Endoscopic Ultrasound
- COMBINATION_PRODUCT Magnetic Resonance Imaging
- COMBINATION_PRODUCT Magnetic Resonance Cholangiopancreatography
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2041-10-31 |
| Phase | Early Phase 1 |
What NCT06122896 shows while recruiting
NCT06122896 is an interventional study that assigns participants to a tested intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 375-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (1233% higher).
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Screening Blood Tests is the first listed.
NCT06122896 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06122896 about?
NCT06122896 is a clinical study titled "Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals". The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
What is the current status of trial NCT06122896?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 5,000 participants. The study started on 2023-11-21. Estimated completion is 2041-10-31.
What conditions does trial NCT06122896 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasm, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC.
What interventions are being tested in trial NCT06122896?
The interventions under investigation include: Screening Blood Tests (OTHER), Endoscopic Ultrasound (DIAGNOSTIC_TEST), Magnetic Resonance Imaging (COMBINATION_PRODUCT), Magnetic Resonance Cholangiopancreatography (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06122896?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122896 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06122896's enrollment target sits among peer trials
5,000 5th of 278 higher than 272 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Lidocaine Infusion in Pancreatic Cancer
RECRUITING · Early Phase 1
-
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI